Início › Leucemia Bifenotípica Aguda › Washington
Ensaios clínicos de Leucemia Bifenotípica Aguda em Washington
15 estudos para Leucemia Bifenotípica Aguda estão buscando participantes em locais em Washington.
Cidades em Washington
Texto oficial do estudo (Inglês)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
RecrutandoFase 1
Idades de 12 a 78 · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07094750CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04375631Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- e mais 1
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 2
6 Months – 65 Years · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 20 de jul. de 2026 · NCT07046078211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 1/2
Idades de 18 a 75 · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 1/2
Idades de 18 a 75 · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT03670966Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 2Voluntários saudáveis bem-vindos
6 Months · Todos os sexos · Atualizado em 29 de mai. de 2026 · NCT04195633HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 1
Até 80 anos · Todos os sexos · Atualizado em 18 de mai. de 2026 · NCT03326921Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 1/2Voluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 15 de mai. de 2026 · NCT06928662Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de abr. de 2026 · NCT04797767Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Seattle Children's Hospital, Seattle
RecrutandoFase 1
Idades de 1 a 21 · Todos os sexos · Atualizado em 6 de dez. de 2024 · NCT05476770Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.